Mike is a 46-year-old who presents with a complaint of “heartburn” for 3 months. He describes the pain as burning located in the epigastric area. The pain improves after he takes an antacid or drinks milk. He has been taking either over-the-counter (OTC) famotidine or ranitidine off and on for the past 2 months, and he still has recurring epigastric pain. He has lost 6 pounds since his last visit. Assessment His examination is unremarkable. His blood pressure (BP) is 118/72 mm Hg. Laboratory values are: normal complete blood count (CBC) and a positive serum Helicobacter pylori test.
1. What would be the initial management plan for a patient with peptic ulcer disease caused by H. pylori?
initial management plan for a patient with peptic ulcer disease caused by H. pylori:
First-line treatment would involve triple therapy with a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole for 10-14 days (Malfertheiner et al., 2017). Specific regimens include:
Omeprazole 20mg, clarithromycin 500mg, and amoxicillin 1000mg – all twice daily for 10-14 days
Pantoprazole 40mg, clarithromycin 500mg, and metronidazole 500mg – all twice daily for 10-14 days
Additionally:
Advise the patient to avoid foods that trigger reflux and ulcer pain such as coffee, alcohol, chocolate, fatty foods, and spicy foods during treatment (Sung et al., 2009).
Follow-up testing should be done through fecal antigen testing, urea breath testing, or gastric biopsy 4-6 weeks after completion of therapy to confirm H. pylori eradication (Chey et al., 2017).
For patients with refractory ulcers despite H. pylori treatment, long-term PPI therapy may be indicated along with retesting for H. pylori using a different testing modality than before (Malfertheiner et al., 2017).
If initial treatment fails, second line therapy involves PPI quadruple therapy with metronidazole, tetracycline, bismuth subsalicylate, and a PPI for 10-14 days (Sung et al., 2009; Malfertheiner et al., 2017).
Along with pharmacotherapy, provide the patient education on dietary and lifestyle modifications to help manage ulcer symptoms. Routine follow-up is also key.
______________________
Management of Helicobacter pylori-Associated Peptic Ulcer Disease
Introduction
Helicobacter pylori (H. pylori) infection is a common cause of peptic ulcer disease. Eradication of H. pylori in patients with peptic ulcers is vital to facilitate ulcer healing and prevent recurrence. This paper discusses recommendations for initial management of peptic ulcer disease caused by H. pylori.
First-Line Treatment
The recommended first-line treatment is triple therapy using a proton pump inhibitor (PPI) along with clarithromycin and either amoxicillin or metronidazole for 10-14 days (Malfertheiner et al., 2017). Common regimens include:
Omeprazole 20mg, clarithromycin 500mg, and amoxicillin 1000mg – all taken twice daily for 10-14 days
Pantoprazole 40mg, clarithromycin 500mg, and metronidazole 500mg – all taken twice daily for 10-14 days
Patients should avoid foods that can trigger reflux during treatment like coffee, alcohol, chocolate, fatty foods, and spicy foods (Sung et al., 2009).
Follow-up testing to confirm H. pylori eradication should be done using the fecal antigen test, urea breath test, or gastric biopsy 4-6 weeks after completing antibiotic therapy (Chey et al., 2017). For those with refractory ulcers despite H. pylori treatment, long-term PPI use and retesting for H. pylori using a different modality than prior should be considered (Malfertheiner et al., 2017).
Second-Line Therapy
For patients in whom initial treatment fails, second-line therapy involves a PPI quadruple therapy with metronidazole, tetracycline, bismuth subsalicylate, and a PPI taken for 10-14 days (Sung et al., 2009; Malfertheiner et al., 2017). This provides an alternative antibiotic combination to target resistant H. pylori strains.
Adjunctive Recommendations
Along with pharmacological treatment, providing patients with education on dietary and lifestyle changes can help augment symptom management. Routine follow-up monitoring is also essential for ensuring ulcer healing and reducing recurrence risk.
Conclusion
Eradicating H. pylori infection is key for peptic ulcer disease management. An initial course of triple therapy with a PPI plus antibiotics followed by confirmatory testing guides appropriate first-line treatment. Second-line quadruple therapy can overcome antibiotic resistance. Ongoing patient education, lifestyle changes, and monitoring is integral for optimal outcomes.
References
Chey, W.D., Leontiadis, G.I., Howden, C.W., Moss, S.F. (2017). ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology, 112(2), 212–238.
Malfertheiner, P., Megraud, F., O’Morain, C.A., Gisbert, J.P., Kuipers, E.J., Axon, A.T., … European Helicobacter and Microbiota Study Group and Consensus panel. (2017). Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut, 66(1), 6–30.
Sung, J.J., Chan, F.K., Chen, M., Ching, J.Y., Ho, K.Y., Kachintorn, U., … Asia-Pacific Working Group. (2009). Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut, 68(10), 1757–1768.
